Women in Biotech

** Registration has now closed for this event **

If you have booked to attend and have any issues accessing the platform or haven't received the instructions, please email gtreen@bioindustry.org 

Thursday 4 June 2020

Following a very successful first event of the year in March, we are excited to bring you our first virtual Women in Biotech event this June.

The BIA’s Women in Biotech event series has been running for over 12 years and aims to connect, inspire, and support women across the sector.

Challenge and opportunity: AI in biotech

We have four fantastic speakers whose professional capacities focus on artifical intelligence within biotechnology.

We’ll be asking them about their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedical research and how we can avoid the pitfalls.


16.30   Sign in and networking

17.00   Welcome
Jane Wall, Director of Business Development and Membership Services, BIA
               Sally Shorthose, Partner, Bird & Bird

17.10  Discussion and Q&A
              Chair: Veronique Bouchet, Chief Medical Officer, PrecisionLife Ltd
              Noor Shaker, Founder/CEO, Glamorous AI
              Sara-Jane Dunn, Research Scientist, Google DeepMind
              Peju Oshisanya, Director, Clinical Programme Leader, BenevolentAI

18:00  Closing remarks
18.05  Networking
19:30  Event closes

Virtual format & tech requirements

We are excited to bring you this Women in Biotech event in virtual format.

You will be able to join us online to network and, similar to an in-person event, move from virtual table to table to mingle with other attendees. The platform we will be using also includes useful features which will allow you to message directly with other attendees and share LinkedIn details to connect. There is also a general chat for all attendees.

During the panel discussion you will be able to submit and vote on audience questions and we will try our best to cover everything in the time allocated.

What are the technical requirements to attend the virtual event?

  • There is no software installation or download required.
  • Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone). The mobile or tablet views are still in the beta stage.
  • You will need to use one of the supported browsers to have the best user experience:
    Chrome, Safari, or Firefox.
  • If you want to check the technical requirements in more detail, you can view their checklist here.

If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.

Costs and T&Cs

We have updated our ticket costs with new pricing for the virtual format.

BIA members - £15 +VAT
Non-members - £25 +VAT

By registering to this event you accept our Terms & Conditions

If you have any questions or problems registering, please contact biaevents@bioindustry.org


Dr Véronique Bouchet

Chief Medical Officer


Véronique is the CMO of PrecisionLife Ltd, an AI enabled precision medicine company, with over 30 years’ experience in the pharmaceutical, biotech and digital health sectors.

She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS. This varied experience has given her an in-depth understanding of what is required to translate cutting edge science into commercial reality. Véronique is the Senior Independent Director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst.

She is a member of Oxford University's Expert Panel supporting The Royal Society Entrepreneur in Residence (EiR) scheme, and also sits on the Advisory Board of QMUL School of Business and Management. She was recognised as one of 50 Movers and Shakers challenging the status quo to bring better health in BioBusiness 2019.

Noor Shaker

Founder and CEO

Glamorous AI

Noor is a serial biotech entrepreneur with a track record of achievements in AI having held an Assistant Professorship from Aalborg University. Noor has published numerous papers in the field of artificial intelligence and its application to drug discovery and is an inventor on a handful of patents. She is passionate about data and AI and on a mission to cure disease with the power of human and machine learning. She is currently the CEO at GlamorousAI, a biotech company that pushes the boundaries to what is possible with AI to cure debilitating diseases. She is a recognised healthcare leader, MIT innovator under 35 and in BBC 100 women for 2019.

Sara-Jane Dunn

Research Scientist

Google DeepMind

Sara-Jane is a Research Scientist at Google DeepMind. She has a Masters in Mathematics from the University of Oxford, where she also achieved her doctorate in Computational Biology. Prior to DeepMind she was a Principal Scientist at Microsoft Research, having joined as a Postdoctoral Researcher in 2012. She is an Affiliate PI of the Wellcome-MRC Stem Cell Institute, University of Cambridge. Her research interests are in the domain of biological computation: how we can uncover the fundamental principles of biological information-processing, and use this understanding to tackle important, impactful problems in the field.

Peju Oshisanya MSc, BSc (HONS)

Director, Clinical Programme Leader


An advocate for diversity and inclusion in data generation in clinical research, Peju is passionate about raising awareness about the importance of including a more diverse popuation in research and the potential benefits of Artificial Intelligence in enabling this.

Peju is an innovative operational strategy expert with over 18 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She started her career working in early drug discovery and exploratory phase focused on the transition of early stage assets to clinical development. Following this, she moved into programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda.

After gaining extensive experience with major pharmaceutical organisations, Peju has moved her career to working with start-up organisations and SMEs. In her current role as director of programme management, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes in a pioneering startup that harnesses artificial intelligence to accelerate and enhance scientific discovery.

Sally Shorthose


Bird & Bird

Sally has wealth of experience working with businesses at the cutting edge of research and technology and whose intellectual property is of prime importance.
Sally is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and ‘freedom to operate’ matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, she provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand alone transactions and as part of an acquisition, divestment or investment activity.
Sally speaks on a variety of IP and regulatory life sciences topics at conferences and contributes to many leading publications; she is also the editor of the The Guide to EU Pharmaceutical Regulatory Law (published by Kluwer Law International), which is written entirely by the team at Bird & Bird with contributions from many offices. Sally is also leading the Bird & Bird Brexit Steering Committee; she gives regular talks and has published several articles on the implications of Brexit for the life sciences and medical devices industries.

Jane Wall

Director of Business Development and Membership Services


Jane joined the BIA in March 2016 as Director of Business Development and Membership Services, with overall responsibility for the recruitment and retention of members, development and delivery of membership services and BIA events.

Prior to this role and a short spell at the Food and Drink Federation assisting with membership development, she held the positions of Associate Director and Head of Sales & Marketing over a period of seven years at the Fire Protection Association – leading on membership and member events, publications, risk services, sales and marketing, CRM implementation and digital presence. Jane’s experience prior to this included Business Development Manager within tech transfer at Oxford Brookes University, four years at T&F/Informa Journals as Managing Editor and Publisher, and reference publishing at Oxford University Press and IBSS (International Bibliography of Social Sciences).

Jane holds a first degree in Italian and European Literature from Warwick University, an MA in Social Anthropology from SOAS, and an MBA from Oxford Brookes Business School.


Thank you to our Women in Biotech series sponsor



BIA Annual Supporters